Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma

CardioVascular and Interventional Radiology

Volumn 36, Issue 3, 2013, Pages 714-723

  Moreno Luna, Laura E ^a   Yang, Ju Dong ^a   Sanchez, William ^a   Paz Fumagalli, Ricardo ^b   Harnois, Denise M ^b   Mettler, Teresa A ^a   Gansen, Denise N ^a   De Groen, Piet C ^a   Lazaridis, Konstantinos N ^a   Narayanan Menon, K V ^a   Larusso, Nicholas F ^a   Alberts, Steven R ^c   Gores, Gregory J ^a   Fleming, Chad J ^a   Slettedahl, Seth W ^d   Harmsen, William S ^d   Therneau, Terry M ^d   Wiseman, Gregory A ^a   Andrews, James C ^a   Roberts, Lewis R ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c MAYO CLINIC CANCER CENTER   (United States)

^d Mayo Clinic   (United States)

Author keywords

Chemoembolization; Efficacy; Hepatocellular carcinoma; Radioembolization; Safety; Yttrium 90

Indexed keywords

MICROSPHERE; YTTRIUM 90;

ABDOMINAL PAIN; ADULT; AGED; APPLICATION SITE BLEEDING; ARTICLE; ARTIFICIAL EMBOLISM; CANCER STAGING; CANCER SURVIVAL; CASE CONTROL STUDY; CHEMOEMBOLIZATION; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; FATIGUE; FEMALE; FEVER; HEADACHE; HERPES ZOSTER; HUMAN; INOPERABLE CANCER; INTERMETHOD COMPARISON; LENGTH OF STAY; LIVER ABSCESS; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; OVERALL SURVIVAL; PATIENT SAFETY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STOMACH ULCER; SURVIVAL RATE; SURVIVAL TIME; THORAX PAIN; TRANSARTERIAL RADIOEMBOLIZATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CHEMOEMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MICROSPHERES; MIDDLE AGED; NEOPLASM STAGING; RADIOTHERAPY DOSAGE; REGISTRIES; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 84877736584     PISSN: 01741551     EISSN: 1432086X     Source Type: Journal    
DOI: 10.1007/s00270-012-0481-2     Document Type: Article

References (28)

1. Everhart JE, Ruhl CE (2009) Burden of digestive diseases in the United States part II: lower gastrointestinal diseases. Gastroenterology 136(3):741-754
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127(12):2893-2917
3. Schwartz M, Roayaie S, Konstadoulakis M (2007) Strategies for the management of hepatocellular carcinoma. Nat Clin Pract Oncol 4(7):424-432
4. Yang JD, Roberts LR (2010) Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol 7(8):448-458
5. Bruix J, Sherman M, Llovet JM et al. (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona 2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35(3):421-430
6. Geschwind JF, Salem R, Carr BI et al. (2004) Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 127(5 Suppl 1):S194-S205
7. Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42(5):1208-1236
8. Llovet JM, Real MI, Montana X et al. (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359(9319):1734-1739
9. Lo CM, Ngan H, Tso WK et al. (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35(5):1164-1171
10. Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37(2):429-442
11. Carr BI (2004) Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: Interim safety and survival data on 65 patients. Liver Transpl 10(2 Suppl 1):S107-S110
12. Lewandowski RJ, Kulik LM, Riaz A et al. (2009) A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant 9(8):1920-1928
13. Hilgard P, Hamami M, Fouly AE et al. (2010) Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology 52(5):1741-1749
14. Kulik LM, Carr BI, Mulcahy MF et al. (2008) Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 47(1):71-81
15. Salem R, Lewandowski RJ, Mulcahy MF et al. (2010) Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 138(1):52-64
16. EASL-EORTC (2012) Clinical practice guidelines Management of hepatocellular carcinoma. J Hepatol 56(4):908-943
17. Carr BI, Kondragunta V, Buch SC, Branch RA (2010) Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. Cancer 116(5):1305-1314
18. D'Avola D, Lnarrairaegui M, Bilbao JI et al. (2009) A retrospective comparative analysis of the effect of Y90-radioembolization on the survival of patients with unresectable hepatocellular carcinoma. Hepatogastroenterology 56(96):1683-1688
19. Kooby DA, Egnatashvili V, Srinivasan S et al. (2010) Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol 21(2):224-230
20. Lambert B, Sturm E, Mertens J et al. (2011) Intra-arterial treatment with 90Y microspheres for hepatocellular carcinoma: 4 years experience at the Ghent University Hospital. Eur J Nucl Med Mol Imaging 38(12):2117-2124
21. Lance C, McLennan G, Obuchowski N et al. (2011) Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma. J Vasc Interv Radiol 22(12):1697-1705
22. Salem R, Lewandowski RJ, Kulik L, et al. (2011) Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 140(2):497-507, e492
23. Sangro B, Carpanese L, Cianni R et al. (2011) Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona Clinic liver cancer stages: a European evaluation. Hepatology 54(3):868-878
24. Lencioni R, Llovet JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30(1):52-60
25. Bruix J, Sherman M (2011) Management of hepatocellular carcinoma: an update. Hepatology 53(3):1020-1022
26. Llovet JM, Di Bisceglie AM, Bruix J et al. (2008) Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100(10):698-711
27. Sangro B, Gil-Alzugaray B, Rodriguez J et al. (2008) Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer 112(7):1538-1546
28. Wong CY, Qing F, Savin M et al. (2005) Reduction of metastatic load to liver after intraarterial hepatic yttrium-90 radioembolization as evaluated by [18F]fluorodeoxyglucose positron emission tomographic imaging. J Vasc Interv Radiol 16(8):1101-1106